var data={"title":"Pylephlebitis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pylephlebitis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pylephlebitis/contributors\" class=\"contributor contributor_credentials\">Denis Spelman, MBBS, FRACP, FRCPA, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pylephlebitis/contributors\" class=\"contributor contributor_credentials\">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pylephlebitis/contributors\" class=\"contributor contributor_credentials\">Allyson Bloom, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pylephlebitis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 18, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pylephlebitis, or infective suppurative thrombosis of the portal vein, is a serious condition with significant morbidity and mortality, which can complicate intraabdominal sepsis of any etiology. Although universally fatal in the preantibiotic era [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/1\" class=\"abstract_t\">1</a>], the outcome of this infection has improved somewhat with modern diagnostic and therapeutic modalities. Curiously, however, reports of the diagnosis have increased in the last 15 years, possibly as a result of newer, more sensitive imaging techniques [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The portal vein is formed by the union of the superior mesenteric vein with the splenic veins. The portal system drains blood from the abdominal section of the gastrointestinal tract, with the exception of the lower part of the rectum.</p><p>Pylephlebitis begins with thrombophlebitis of small veins draining an area of infection. Extension of the thrombophlebitis into larger veins leads to septic thrombophlebitis of the portal vein, which can extend further to involve the mesenteric veins [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/3\" class=\"abstract_t\">3</a>]. In a review of case reports, the superior mesenteric vein was involved in 42 percent [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/4\" class=\"abstract_t\">4</a>]. Thrombus involved the splenic vein and intrahepatic branches of the portal vein in 12 and 39 percent of cases, respectively. Mesenteric vein involvement can lead to bowel ischemia, infarction and death.</p><p>An associated hypercoagulable state is found in some cases of pylephlebitis [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/5\" class=\"abstract_t\">5</a>]. As an example, in one series of 44 cases, 18 were hypercoagulable due to clotting factor deficiencies, malignant conditions, or AIDS [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pylephlebitis can complicate any intraabdominal or pelvic infection that occurs in the region drained by the portal venous system, especially diverticulitis and appendicitis (<a href=\"image.htm?imageKey=ID%2F71532\" class=\"graphic graphic_figure graphicRef71532 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2,6-8\" class=\"abstract_t\">2,6-8</a>]. In a 1948 report, the most common inciting infection was appendicitis, accounting for all 21 cases [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/9\" class=\"abstract_t\">9</a>]. However, the incidence of pylephlebitis following appendicitis significantly decreased with the introduction of antibiotics [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/1\" class=\"abstract_t\">1</a>]. One of the most frequent foci is diverticulitis, which accounted for 6 of 18 cases in one series [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2\" class=\"abstract_t\">2</a>]. Although diverticulitis is a common cause of pylephlebitis, pylephlebitis remains a rare complication of diverticulitis [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/1\" class=\"abstract_t\">1</a>]. </p><p>Contiguous infection (eg, cholangitis or infected choledocholithiasis) can also lead to this complication [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2,10\" class=\"abstract_t\">2,10</a>]. In addition, pylephlebitis has been associated with inflammatory bowel disease [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/7,11-13\" class=\"abstract_t\">7,11-13</a>], pancreatitis [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/4,14\" class=\"abstract_t\">4,14</a>], hemorrhoidal banding [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/15\" class=\"abstract_t\">15</a>], and has occurred as a complication of the intragastric migration of a silicone gastric band [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/16\" class=\"abstract_t\">16</a>] and following a computed tomography (CT)-guided liver biopsy [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/17\" class=\"abstract_t\">17</a>]. A precipitating focus was identified in 13 of 18 cases (68 percent) in one report [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2\" class=\"abstract_t\">2</a>]. Pylephlebitis due to <em>Bacteroides</em> in a patient with <em>Strongyloides</em> infection has also been reported [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/18\" class=\"abstract_t\">18</a>]. In Taiwan, primary liver abscess due to <em>Klebsiella pneumoniae</em> has emerged as a precipitating factor for pylephlebitis [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/19\" class=\"abstract_t\">19</a>]. (See <a href=\"topic.htm?path=invasive-liver-abscess-syndrome-caused-by-klebsiella-pneumoniae\" class=\"medical medical_review\">&quot;Invasive liver abscess syndrome caused by Klebsiella pneumoniae&quot;</a>.)</p><p>The age range of affected patients is wide (6 to 75 years), which may partially be influenced by the number of patients with appendicitis as an inciting etiology. The mean age of patients with pylephlebitis is approximately 42 years, and in one review, 24 percent were aged &lt;18 years [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/4\" class=\"abstract_t\">4</a>]. </p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bacteremia associated with pylephlebitis is frequently polymicrobial. In one review of 19 cases, bacteremia occurred in 88 percent; the most common bloodstream isolates were <em>Bacteroides fragilis</em> and <em>Escherichia coli</em>, but other organisms (eg, <em>Aeromonas hydrophila</em>, streptococci, <em>Proteus mirabilis</em>, <em>K. pneumoniae</em>, anaerobic streptococci, and <em>Clostridium</em> spp) were also isolated [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2\" class=\"abstract_t\">2</a>]. In a subsequent series of 95 cases, bacteremia occurred in 44 percent, and the most common isolate was <em>Streptococcus viridans </em>[<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/14\" class=\"abstract_t\">14</a>].</p><p>Yeasts, other streptococci, staphylococci, and <em>Citrobacter </em>spp have also been described, but enterococci are an uncommon cause of this entity [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2,6\" class=\"abstract_t\">2,6</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Abdominal pain, which is not necessarily severe, and fever are the most common presenting symptoms of pylephlebitis. In one report, all 44 patients had these two complaints [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/6\" class=\"abstract_t\">6</a>]. By contrast, 100 percent had fever but only 14 (74 percent) complained of abdominal pain in another review of 19 cases [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2\" class=\"abstract_t\">2</a>]. Other symptoms have included rigors, nausea, vomiting, and headache [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/1,2,20\" class=\"abstract_t\">1,2,20</a>]. </p><p>Clinical signs may include right upper quadrant or generalized abdominal tenderness, hepatomegaly, and jaundice. However, jaundice appears to be unusual in pylephlebitis unless there is associated cholangitis or liver abscess [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2\" class=\"abstract_t\">2</a>]. Splenomegaly has been reported in 10 to 25 percent of cases of pylephlebitis [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/4,21\" class=\"abstract_t\">4,21</a>].</p><p>Patients may have minimal or no clinical features referable to the primary focus of infection, similar to patients with liver abscess [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/7\" class=\"abstract_t\">7</a>] (see <a href=\"topic.htm?path=pyogenic-liver-abscess\" class=\"medical medical_review\">&quot;Pyogenic liver abscess&quot;</a>). Although pylephlebitis usually presents as an acute illness, it may also present with a chronic or stuttering course over weeks [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/3,22\" class=\"abstract_t\">3,22</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Laboratory findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Leukocytosis is a common finding [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/1,11,20,23\" class=\"abstract_t\">1,11,20,23</a>], but both a normal leukocyte count [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2,21,23\" class=\"abstract_t\">2,21,23</a>] and neutropenia [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/7\" class=\"abstract_t\">7</a>] have also been described. Abnormal liver function tests, especially three- to fourfold increases in alkaline phosphatase [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/1,7,11,20\" class=\"abstract_t\">1,7,11,20</a>] and 5- to 10-fold increases in gamma glutamyl transferase [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/8,11\" class=\"abstract_t\">8,11</a>], are noted in most patients [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/1\" class=\"abstract_t\">1</a>]. However, in keeping with the relative infrequency of clinical jaundice, two- to sixfold increases in serum bilirubin occur only in selected cases [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/1,7,11,20\" class=\"abstract_t\">1,7,11,20</a>]. The inciting intraabdominal sepsis or complicating hepatic abscesses may also contribute to hepatic dysfunction.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pyogenic liver abscesses can complicate cases of pylephlebitis; in one series, they were reported in 37 percent of cases [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/1,4,24-26\" class=\"abstract_t\">1,4,24-26</a>]. Bowel ischemia has also rarely been reported with one case of small bowel infarction necessitating bowel resection [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/4,5\" class=\"abstract_t\">4,5</a>]. Portal hypertension may be a long term complication of pylephlebitis and has been described in a small number of cases [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/4,7\" class=\"abstract_t\">4,7</a>]. Further sequelae of portal hypertension can include a dilated splenic vein and numerous venous collaterals in the hepatoduodenal ligament [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/21\" class=\"abstract_t\">21</a>]. (See <a href=\"topic.htm?path=pyogenic-liver-abscess\" class=\"medical medical_review\">&quot;Pyogenic liver abscess&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of pylephlebitis requires the demonstration of portal vein thrombosis (pylethrombosis) usually accompanied by bacteremia in a febrile patient [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/23\" class=\"abstract_t\">23</a>]. The diagnosis is frequently delayed because pylephlebitis is not considered since it is an uncommon condition, or because symptoms are nonspecific, clinical signs are typically lacking from the primary focus of infection, and there may be poor visualization of the portal vein. The diagnosis was most often made at laparotomy or postmortem in the past, but modern imaging techniques now facilitate an earlier diagnosis.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Blood cultures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bacteremia has been documented in 23 to 88 percent of cases [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2,6,14\" class=\"abstract_t\">2,6,14</a>]. For this reason, blood cultures should be obtained in any febrile patient with abdominal pain.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Imaging studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The demonstration of thrombus in the portal vein is an important component of the diagnosis of pylephlebitis but is not sufficient by itself. The diagnostic imaging modality of choice depends on the expertise at the institution where the studies are performed. Both computed tomography (CT) scanning and ultrasonography can demonstrate thrombus in the portal vein (<a href=\"image.htm?imageKey=RADIOL%2F91203\" class=\"graphic graphic_diagnosticimage graphicRef91203 \">image 1</a>), with or without associated mesenteric vein thrombus [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/21\" class=\"abstract_t\">21</a>]. In up to 18 percent of cases, gas can be visualized in the portal system [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/4\" class=\"abstract_t\">4</a>]. We prefer the CT scan as the imaging study because of the additional ability to identify an underlying focus of infection elsewhere in the abdomen or pelvis.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Computed tomography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The CT scan is diagnostic when it demonstrates portal vein thrombosis in a patient with a clinical picture consistent with pylephlebitis (<a href=\"image.htm?imageKey=RADIOL%2F91203\" class=\"graphic graphic_diagnosticimage graphicRef91203 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/1,21,27\" class=\"abstract_t\">1,21,27</a>]. CT scanning has also been useful in defining a precipitating focus of infection.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Ultrasound</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ultrasonography can demonstrate echogenic material within the lumen of the portal vein and can also be used to evaluate progression or extension of clot and subsequent recanalization [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/7\" class=\"abstract_t\">7</a>]. Color flow Doppler ultrasonography may improve diagnostic accuracy [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/1\" class=\"abstract_t\">1</a>]. Intraoperative ultrasonography has also been used to confirm the diagnosis of pylephlebitis when this entity is suspected preoperatively [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/21\" class=\"abstract_t\">21</a>].</p><p class=\"headingAnchor\" id=\"H433921002\"><span class=\"h3\">Other studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Magnetic resonance imaging (MRI) has been used to demonstrate portomesenteric vein thrombosis [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/14\" class=\"abstract_t\">14</a>]. There are occasional but limited reports of fluorodeoxyglucose positron emission tomography (FDG-PET) being useful in the diagnosis of pylephlebitis in patients with fever of unknown origin [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antibiotics constitute the major treatment approach to pylephlebitis.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Antibiotics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The choice of empiric antibiotics in pylephlebitis depends on the probable source of infection and the likely organisms (see <a href=\"#H4\" class=\"local\">'Microbiology'</a> above). Infection is often polymicrobial, with both gram-negative aerobes and anaerobes, especially <em>B. fragilis</em>. Successful antibiotic regimens have included <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a> [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/29\" class=\"abstract_t\">29</a>], third generation cephalosporins [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/7\" class=\"abstract_t\">7</a>], fluoroquinolones [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/7\" class=\"abstract_t\">7</a>], <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/7\" class=\"abstract_t\">7</a>], <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2\" class=\"abstract_t\">2</a>], <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2\" class=\"abstract_t\">2</a>], and <a href=\"topic.htm?path=lincomycin-drug-information\" class=\"drug drug_general\">lincomycin</a> (not available in the United States) [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Recommended regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pylephlebitis is an uncommon infection, and thus, no randomized controlled studies have evaluated empiric antibiotic regimens for this disease. Treatment regimens are based on coverage of the most likely organisms to cause infection in this setting and small case series. We recommend that empiric treatment include broad-spectrum antibiotics until culture results are available. Patients should be treated at least initially with parenteral antibiotics.</p><p>Appropriate antibiotics include any of the following parenteral regimens:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Combination therapy with <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> (500 mg every eight hours) PLUS one of the following, <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a> (2 g daily) OR <a href=\"topic.htm?path=cefotaxime-drug-information\" class=\"drug drug_general\">cefotaxime</a> (2 g every six hours) OR <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> (400 mg every 12 hours) OR <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> (500 mg daily)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Monotherapy with a <span class=\"nowrap\">beta-lactam/beta-lactamase</span> inhibitor, such as, <a href=\"topic.htm?path=piperacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">piperacillin</a><span class=\"nowrap\">/tazobactam</span> (4.5 g every six hours) OR <a href=\"topic.htm?path=ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information\" class=\"drug drug_general\">ticarcillin-clavulanate</a> (3.1 g every four hours) OR <a href=\"topic.htm?path=ampicillin-and-sulbactam-drug-information\" class=\"drug drug_general\">ampicillin-sulbactam</a> (3 g every six hours)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Monotherapy with a carbapenem, such as <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a> (500 mg every six hours) OR <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a> (1 g every eight hours) OR <a href=\"topic.htm?path=ertapenem-drug-information\" class=\"drug drug_general\">ertapenem</a> (1 g daily)</p><p/><p>The initial antibiotic choice should be modified if blood or surgical (from the underlying focus of infection) culture results and antimicrobial susceptibility testing are available. Susceptibility testing for anaerobes are not routinely performed but should be considered, especially in patients who are failing therapy.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Duration of therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The typical duration of antibiotic therapy is at least four to six weeks [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2\" class=\"abstract_t\">2</a>]. Parenteral antibiotics are given until there is significant clinical response, usually about two to three weeks. The remainder of the antibiotic course can be completed with oral agents, such as the combination of oral <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> and a fluoroquinolone.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Anticoagulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no prospective randomized controlled studies and no consensus on the use of anticoagulation in pylephlebitis. The rationale for anticoagulation in acute pylephlebitis is the prevention of thrombus extension and its sequelae.</p><p>In a report of 100 selected cases of pylephlebitis from the literature, 35 received anticoagulation [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/4\" class=\"abstract_t\">4</a>]. There were fewer deaths among those who received anticoagulation compared with those who received antibiotics alone (6 versus 22 percent). Similarly, a retrospective review of 44 patients with pylephlebitis, diagnosed with computed tomography (CT) scan and consistent clinical symptoms, found that patients who received anticoagulation had a better outcome than those who did not (0 of 12 versus 5 of 32 deaths) [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/6\" class=\"abstract_t\">6</a>]. Based upon these findings, the authors of this review suggest the following role of anticoagulation therapy:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anticoagulation is probably unnecessary in the patient with normal clotting function and thrombosis isolated to the portal vein. However, if there is mesenteric vein involvement, patients may benefit from anticoagulation, since the risk of bowel ischemia and infarction may be higher.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anticoagulation should be considered in the patient with a hypercoagulable state (eg, due to a neoplasm or clotting factor deficiency).</p><p/><p>Further support for anticoagulation in patients with pylephlebitis comes from a retrospective case series of patients with recent portal or mesenteric thrombosis, which found that recanalization occurred in 25 of 27 patients given anticoagulation [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/30\" class=\"abstract_t\">30</a>]. In addition, a case report of anticoagulation after extension of thrombus documented prompt resolution of the clot [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/7\" class=\"abstract_t\">7</a>]. The authors of this case report suggest that if there is acute extension of thrombosis, documented progression, or persistent fever unresponsive to antibiotic therapy, anticoagulation should be considered.</p><p><em>Bacteroides</em> spp appear to promote coagulation, as these organisms produce enzymes that break down heparin and <em>Bacteroides</em> spp surface components promote fibrin clotting [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/3\" class=\"abstract_t\">3</a>]. The isolation of this organism from a patient may influence the decision, favoring anticoagulation.</p><p>However, other studies have noted no benefit from anticoagulation. A retrospective review of 19 patients with pylephlebitis found no clear improvement attributed to the use of heparin&nbsp;[<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2\" class=\"abstract_t\">2</a>].</p><p>When anticoagulation is used, the clinical endpoint is uncertain. Recanalization has been documented in some cases, but the length of time required for this to occur is unknown.</p><p>Thrombolytic therapy is an additional option when thrombosis progresses [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/7\" class=\"abstract_t\">7</a>], but there is minimal experience with this treatment in pylephlebitis and no conclusive evidence of efficacy [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/31\" class=\"abstract_t\">31</a>].</p><p>We suggest not treating most patients with anticoagulation unless there is evidence of progression of thrombosis or continued fever or bacteremia despite antibiotic therapy.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Percutaneous techniques</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Catheter insertion into the portal vein with aspiration of thrombus <span class=\"nowrap\">and/or</span> pus has been reported [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/32,33\" class=\"abstract_t\">32,33</a>]. Intraportal infusion of antibiotics has also been described [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/32\" class=\"abstract_t\">32</a>]. Further clinical experience is required before this technique can be routinely recommended.</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surgery is not usually required for the management of pylephlebitis. However, surgical drainage of the precipitating focus may be necessary in some cases.</p><p class=\"headingAnchor\" id=\"H637173734\"><span class=\"h1\">FOLLOW UP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Follow-up imaging (either computed tomography scanning or ultrasonography) of the portal vein during or following therapy is not generally useful in uncomplicated cases. Incomplete resolution of the thrombus is common, and does not preclude clinical improvement [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/4\" class=\"abstract_t\">4</a>]. </p><p>However, in the setting of poor or slow clinical response or if there is subsequent evidence of portal hypertension, additional imaging can be useful to evaluate for thrombus extension or other complications that may prompt changes in management. </p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h1\">OUTCOME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pylephlebitis was uniformly fatal in the 20 cases reported in 1948, secondary to appendicitis [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/9\" class=\"abstract_t\">9</a>]. Even with newer available antibiotics, the condition continues to have an appreciable mortality rate, ranging from 11 to 32 percent [<a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2,6,14\" class=\"abstract_t\">2,6,14</a>].</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pylephlebitis or infective suppurative thrombosis of the portal vein is a serious condition with significant morbidity and mortality, which can complicate intraabdominal sepsis of any etiology. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pylephlebitis begins with thrombophlebitis of small veins draining an area of infection. Extension of the thrombophlebitis into larger veins leads to septic thrombophlebitis of the portal vein, which can extend further to involve the mesenteric veins. (See <a href=\"#H2\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most common predisposing infections leading to pylephlebitis are diverticulitis and appendicitis. (See <a href=\"#H3\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bacteremia, which is frequently polymicrobial, occurred in 88 percent of cases in one series; the most common bloodstream isolates were <em>Bacteroides fragilis</em> and <em>Escherichia coli</em>. (See <a href=\"#H4\" class=\"local\">'Microbiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abdominal pain, which is not necessarily severe, and fever are the most common presenting symptoms of pylephlebitis. (See <a href=\"#H5\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of pylephlebitis requires the demonstration of portal vein thrombosis (pylethrombosis) usually accompanied by bacteremia in a febrile patient. We prefer the computed tomography (CT) scan as the imaging study because of the additional ability to identify an underlying focus of infection elsewhere in the abdomen or pelvis (<a href=\"image.htm?imageKey=RADIOL%2F91203\" class=\"graphic graphic_diagnosticimage graphicRef91203 \">image 1</a>). (See <a href=\"#H8\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend empiric treatment of pylephlebitis include parenteral broad-spectrum antibiotics until culture results are available (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). Typical treatment regimens include one of the following (see <a href=\"#H14\" class=\"local\">'Antibiotics'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Combination therapy with <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> (500 mg every eight hours) PLUS one of the following, <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a> (2 g daily) OR <a href=\"topic.htm?path=cefotaxime-drug-information\" class=\"drug drug_general\">cefotaxime</a> (2 g every six hours) OR <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> (400 mg every 12 hours) OR <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> (500 mg daily)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Monotherapy with a <span class=\"nowrap\">beta-lactam/beta-lactamase</span> inhibitor, such as, <a href=\"topic.htm?path=piperacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">piperacillin</a><span class=\"nowrap\">/tazobactam</span> (4.5 g every six hours) OR <a href=\"topic.htm?path=ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information\" class=\"drug drug_general\">ticarcillin-clavulanate</a> (3.1 g every four hours) OR <a href=\"topic.htm?path=ampicillin-and-sulbactam-drug-information\" class=\"drug drug_general\">ampicillin-sulbactam</a> (3 g every six hours)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Monotherapy with a carbapenem, such as, <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a> (500 mg every six hours) OR <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a> (1 g every eight hours) OR <a href=\"topic.htm?path=ertapenem-drug-information\" class=\"drug drug_general\">ertapenem</a> (1 g daily)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The initial antibiotic choice should be modified once culture results and antimicrobial susceptibility testing are available. (See <a href=\"#H15\" class=\"local\">'Recommended regimens'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The typical duration of antibiotic therapy is at least four to six weeks. (See <a href=\"#H16\" class=\"local\">'Duration of therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest <strong>NOT</strong> treating most patients with anticoagulation unless there is evidence of progression of thrombosis or continued fever or bacteremia despite antibiotic therapy (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H17\" class=\"local\">'Anticoagulation'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/1\" class=\"nounderline abstract_t\">Saxena R, Adolph M, Ziegler JR, et al. Pylephlebitis: a case report and review of outcome in the antibiotic era. Am J Gastroenterol 1996; 91:1251.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/2\" class=\"nounderline abstract_t\">Plemmons RM, Dooley DP, Longfield RN. Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Clin Infect Dis 1995; 21:1114.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/3\" class=\"nounderline abstract_t\">Kasper DL, Sahani D, Misdraji J. Case records of the Massachusetts General Hospital. Case 25-2005. A 40-year-old man with prolonged fever and weight loss. N Engl J Med 2005; 353:713.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/4\" class=\"nounderline abstract_t\">Kanellopoulou T, Alexopoulou A, Theodossiades G, et al. Pylephlebitis: an overview of non-cirrhotic cases and factors related to outcome. Scand J Infect Dis 2010; 42:804.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/5\" class=\"nounderline abstract_t\">Pradka SP, Trankiem CT, Ricotta JJ. Pylephlebitis and acute mesenteric ischemia in a young man with inherited thrombophilia and suspected foodborne illness. J Vasc Surg 2012; 55:1769.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/6\" class=\"nounderline abstract_t\">Baril N, Wren S, Radin R, et al. The role of anticoagulation in pylephlebitis. Am J Surg 1996; 172:449.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/7\" class=\"nounderline abstract_t\">Duffy FJ Jr, Millan MT, Schoetz DJ Jr, Larsen CR. Suppurative pylephlebitis and pylethrombosis: the role of anticoagulation. Am Surg 1995; 61:1041.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/8\" class=\"nounderline abstract_t\">Joly V, Belmatoug N, Sibert A, et al. Septic thrombophlebitis of the portal vein. Clin Infect Dis 1996; 23:417.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/9\" class=\"nounderline abstract_t\">SORO Y. Pylephlebitis and liver abscesses due to appendicitis. J Int Coll Surg 1948; 11:464.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/10\" class=\"nounderline abstract_t\">Tsao YT, Lin SH, Cheng CJ, Chang FY. Pylephlebitis associated with acute infected choledocholithiasis. Am J Med Sci 2006; 332:85.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/11\" class=\"nounderline abstract_t\">Tung JY, Johnson JL, Liacouras CA. Portal-mesenteric pylephlebitis with hepatic abscesses in a patient with Crohn's disease treated successfully with anticoagulation and antibiotics. J Pediatr Gastroenterol Nutr 1996; 23:474.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/12\" class=\"nounderline abstract_t\">Baddley JW, Singh D, Correa P, Persich NJ. Crohn's disease presenting as septic thrombophlebitis of the portal vein (pylephlebitis): case report and review of the literature. Am J Gastroenterol 1999; 94:847.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/13\" class=\"nounderline abstract_t\">Shin AR, Lee CK, Kim HJ, et al. Septic pylephlebitis as a rare complication of Crohn's disease. Korean J Gastroenterol 2013; 61:219.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/14\" class=\"nounderline abstract_t\">Choudhry AJ, Baghdadi YM, Amr MA, et al. Pylephlebitis: a Review of 95 Cases. J Gastrointest Surg 2016; 20:656.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/15\" class=\"nounderline abstract_t\">Chau NG, Bhatia S, Raman M. Pylephlebitis and pyogenic liver abscesses: a complication of hemorrhoidal banding. Can J Gastroenterol 2007; 21:601.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/16\" class=\"nounderline abstract_t\">De Roover A, Detry O, Coimbra C, et al. Pylephlebitis of the portal vein complicating intragastric migration of an adjustable gastric band. Obes Surg 2006; 16:369.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/17\" class=\"nounderline abstract_t\">Tandon R, Davidoff A, Worthington MG, Ross JJ. Pylephlebitis after CT-guided percutaneous liver biopsy. AJR Am J Roentgenol 2005; 184:S70.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/18\" class=\"nounderline abstract_t\">Stone NR, Martin T, Biswas J, et al. Bacteroides-associated pylephlebitis in a patient with strongyloidiasis. Am J Trop Med Hyg 2015; 92:340.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/19\" class=\"nounderline abstract_t\">Wang YF, Chang CC, Lee TC, et al. Recent trend of pylephlebitis in Taiwan: Klebsiella pneumoniae liver abscess as an emerging etiology. Infection 2013; 41:1137.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/20\" class=\"nounderline abstract_t\">Sakamoto H, Suga M, Ozeki I, et al. Subcapsular hematoma of the liver and pylethrombosis in the setting of cholestatic liver injury. J Gastroenterol 1996; 31:880.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/21\" class=\"nounderline abstract_t\">Farin P, Paajanen H, Miettinen P. Intraoperative US diagnosis of pylephlebitis (portal vein thrombosis) as a complication of appendicitis: a case report. Abdom Imaging 1997; 22:401.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/22\" class=\"nounderline abstract_t\">Wireko M, Berry PA, Brennan J, Aga R. Unrecognized pylephlebitis causing life-threatening septic shock: a case report. World J Gastroenterol 2005; 11:614.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/23\" class=\"nounderline abstract_t\">Dean JW, Trerotola SO, Harris VJ, et al. Percutaneous management of suppurative pylephlebitis. J Vasc Interv Radiol 1995; 6:585.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/24\" class=\"nounderline abstract_t\">Nishimori H, Ezoe E, Ura H, et al. Septic thrombophlebitis of the portal and superior mesenteric veins as a complication of appendicitis: report of a case. Surg Today 2004; 34:173.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/25\" class=\"nounderline abstract_t\">Brown KT, Gandhi RT, Covey AM, et al. Pylephlebitis and liver abscess mimicking hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2003; 2:221.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/26\" class=\"nounderline abstract_t\">Chang TN, Tang L, Keller K, et al. Pylephlebitis, portal-mesenteric thrombosis, and multiple liver abscesses owing to perforated appendicitis. J Pediatr Surg 2001; 36:E19.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/27\" class=\"nounderline abstract_t\">Balthazar EJ, Gollapudi P. Septic thrombophlebitis of the mesenteric and portal veins: CT imaging. J Comput Assist Tomogr 2000; 24:755.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/28\" class=\"nounderline abstract_t\">Bleeker-Rovers CP, Jager G, Tack CJ, et al. F-18-fluorodeoxyglucose positron emission tomography leading to a diagnosis of septic thrombophlebitis of the portal vein: description of a case history and review of the literature. J Intern Med 2004; 255:419.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/29\" class=\"nounderline abstract_t\">Perez-Cruet MJ, Grable E, Drapkin MS, et al. Pylephlebitis associated with diverticulitis. South Med J 1993; 86:578.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/30\" class=\"nounderline abstract_t\">Condat B, Pessione F, Helene Denninger M, et al. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32:466.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/31\" class=\"nounderline abstract_t\">Sherigar R, Amir KA, Bobba RK, et al. Abdominal pain secondary to pylephlebitis: an uncommon disease of the portal venous system, treated with local thrombolytic therapy. Dig Dis Sci 2005; 50:983.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/32\" class=\"nounderline abstract_t\">Vivas I, Bilbao JI, Mart&iacute;nez-Cuesta A, et al. Combination of various percutaneous techniques in the treatment of pylephlebitis. J Vasc Interv Radiol 2000; 11:777.</a></li><li><a href=\"https://www.uptodate.com/contents/pylephlebitis/abstract/33\" class=\"nounderline abstract_t\">Pelsang RE, Johlin F, Dhadha R, et al. Management of suppurative pylephlebitis by percutaneous drainage: placing a drainage catheter into the portal vein. Am J Gastroenterol 2001; 96:3192.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2713 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H21\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOGENESIS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">EPIDEMIOLOGY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">MICROBIOLOGY</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">Laboratory findings</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Complications</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">DIAGNOSIS</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Blood cultures</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Imaging studies</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">- Computed tomography</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">- Ultrasound</a></li><li><a href=\"#H433921002\" id=\"outline-link-H433921002\">- Other studies</a></li></ul></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">TREATMENT</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">Antibiotics</a><ul><li><a href=\"#H15\" id=\"outline-link-H15\">- Recommended regimens</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">- Duration of therapy</a></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">Anticoagulation</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Percutaneous techniques</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Surgery</a></li></ul></li><li><a href=\"#H637173734\" id=\"outline-link-H637173734\">FOLLOW UP</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">OUTCOME</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/2713|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=RADIOL/91203\" class=\"graphic graphic_diagnosticimage\">- CT pylephlebitis</a></li></ul></li><li><div id=\"ID/2713|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/71532\" class=\"graphic graphic_figure\">- Pylephlebitis liver abscess</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=invasive-liver-abscess-syndrome-caused-by-klebsiella-pneumoniae\" class=\"medical medical_review\">Invasive liver abscess syndrome caused by Klebsiella pneumoniae</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pyogenic-liver-abscess\" class=\"medical medical_review\">Pyogenic liver abscess</a></li></ul></div></div>","javascript":null}